Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.57%
#2 Movement Movement +6.40%
#3 Palladium Network Palladium Network +5.02%
#4 Prom Prom +4.17%
#5 GRVT Token GRVT Token +3.87%
#6 Cryptopia Cryptopia +3.74%
#7 SIXSEVEN SIXSEVEN +3.67%
#8 Test Test +3.60%
#9 Kinetiq Kinetiq +3.58%
#10 Jito Jito +3.53%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Settings
Language
ENGLISH
Currency
USD
Theme
Innovation1 Biotech Inc. Innovation1 Biotech Inc.

Innovation1 Biotech Inc.

IVBT
Rank in Stocks #42121
Innovation1 Biotech Inc. functions as a drug discovery enterprise, primarily... Innovation1 Biotech Inc. functions as a drug discovery enterprise, primarily engaged in creating modified botanical Schedule 1 molecules for use within the United States. The firm's pipeline encompasses five entirely synthetic, proprietary prodrugs that are currently in preclinical development, each designed to tackle a unique set of medical conditions. Specifically, these include a psychedelic compound derived from mushrooms, aimed at treating post-traumatic stress disorder and depression; an innovative cannabinoid and tree bark-sourced psychedelic intended to combat addiction; and three additional cannabinoid prodrugs targeting refractory pediatric epilepsy, hypertrophic scarring, and inflammation of the eye. Established in 2014 and headquartered in New York, New York, the company was previously named Gridiron BioNutrients, Inc. before adopting its current moniker, Innovation1 Biotech Inc., in March 2022.
Share Price
$0.0002
Last synced: 2026-08-11
Market Cap
$4.49K
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Innovation1 Biotech Inc. (IVBT)

Category

Healthcare
P/B ratio for Innovation1 Biotech Inc. (IVBT)
P/B ratio as of 2026 TTM: 0
According to Innovation1 Biotech Inc. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0. At the end of 2026 the company had a P/B ratio of 0.
P/B ratio history for Innovation1 Biotech Inc. from 2026 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
Not enough data for the provided dates.
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.2613 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.3483 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 3.634 -
BE
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR